Anavex (AVXL) Life Sciences announced it was issued a new U.S. Patent No. 12,180,174 entitled “A2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOF” from the United States Patent and Trademark Office, USPTO, for its U.S. Patent Application Serial Number USSN: 17/978,818. This new patent claims crystalline forms of the dihydrogen phosphate salt of ANAVEX2-73, freebase, transdermal patches and enteric coated oral dosage forms including the same for neuroprotection and treatment of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and other disorders.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- Largest borrow rate increases among liquid names
- Anavex announces peer-reviewed publication Phase IIb/III data on blarcamesine
- Anavex announces 3 years of treatment with blarcamesine show reduced decline
- Anavex Life Sciences (AVXL) Alzheimer Treatment Sends the Stock to New Heights
- Biotech Alert: Searches spiking for these stocks today